Risky business in myeloma

Blood

Volumn 114, Issue 3, 2009, Pages 496-497

  Lonial, Sagar ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN;

FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; MYELOMA; NOTE; PLASMACYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; TREATMENT RESPONSE;

EID: 70449472463     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-217281     Document Type: Note

References (11)

1. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114:518-521.
2. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522-525.
3. Zonder JA, Crowley J, Hussein MA, et al. Superiority of Lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo = controlled SWOG Trial S0232 [abstract]. Blood. 2007;110. Abstract 77.
4. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.NEngl J Med. 2008;359:906-917.
5. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial [abstract]. J Clin Oncol. 2008; 26. Abstract 8505.
6. Cavo M, Testoni N, Terragna C, et al. Superior rate of complete response with up-front velcade-thalidomide-dexamethasone versus thalidomide-dexamethasone in newly diagnosed multiple myeloma is not affected by adverse prognostic factors, including high-risk cytogenetic abnormalities [abstract]. Blood. 2008;112: 586. Abstract 1662.
7. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158-164. (Pubitemid 44401612)
8. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007; 3489-3495.
9. Moreau P, Attal M, Garban F, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia. 2007;21:2020-2024. (Pubitemid 47299977)
10. Fonseca, et al. International Myeloma Working Group Molecular Classification of Multiple Myeloma. Leukemia. In press.
11. Hoering A, Crowley J, Shanghnessy JD Jr, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood. Prepublished on June 11, 2009, as DOI 10.1182/blood-2009-03-211953.